Overcoming the drug delivery limitations of current LNP approaches
Our ttLNP Platform
Our research and intellectual property portfolio, licensed from Tufts University and built by our founder Dr. Qiaobing Xu over the last decade, provide a strong foundation to develop an extensive and rapidly growing library of ionizable lipids and LNP leads based on our differentiated ttLNP platform.
Our ttLNP platform enables rational design, high throughput screening and optimization of physical and chemical properties and formulation of lipid nanoparticles with diverse cargoes. The proprietary chemistry associated with the creation of ionizable lipids is a key differentiator of Hopewell, and pre-clinical research conducted by Hopewell and industry partners, including in rodents and non-human primates (NHP), have demonstrated high translatability for systemic delivery to targeted tissues across species. Based on research to date, we expect our technology to overcome the drug delivery limitations of current LNP approaches in terms of organ, tissue and cell targeting, biocompatibility and sustained high expression with repeat dosing.
Hopewell’s ttLNPs have been shown, through a decade of peer reviewed publications to deliver a variety of high impact genomic cargoes, including mRNA, siRNA, DNA, gene editing and gene-writing apparatus, to organs, tissues and cells throughout the body, with the potential to impact multiple areas of medicine.
We continue to innovate and expand our ttLNP platform to enable a new generation of highly targeted genomic medicines for patients with unmet medical needs.
Key Scientific Publications
Hopewell was established with scientific data featured in over a decade of leading publications that highlight the novelty of the company's LNP technology and its potential to address the unmet needs of patients.